Pfizer pipeline update. 2024 FINANCIAL GUIDANCE (1).
Pfizer pipeline update With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 3, 2022 15 programs advanced or are new 4 programs discontinued since last update Included are 65 NMEs, 31 additional indications Discovery Projects Phase 1 30 Phase 2 31 Phase 3 29 Registration 6 Total 96 Snapshot as of Pfizer Pipeline May 3, 2022 Discovery Projects With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. (NYSE: PFE) today announced that based on results from the ongoing pharmacokinetic study (NCT06153758), the company has selected its preferred once-daily modified release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Oncology (2 of 2) Compound Name Mechanism of last update Phase 2 Phase 3 33 16 30 7 86 Phase 1 Total Discovery Projects 6 programs advanced or are new 5 projects discontinued since last update Pfizer Pipeline Snapshot as of August 2, 2016 Pfizer Pipeline Snapshot as of May 3, 2016 Registration Recent Approvals - Ibrance (palbociclib) for Recurrent Advanced Breast Cancer (US) (BUSINESS WIRE)--Pfizer Inc today provided an update to its pipeline, highlighting the progression of clinical programs in high-priority therapeutic areas, and announced the start of Phase 3 clinical trials for two new molecular entities. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A. 2 is the preferred strain for COVID-19 vaccines for the US 2024-2025 fall and winter season, if feasible Shipping will begin Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 17 programs advanced or are new 2 programs discontinued since last update Included are 68 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 37 Phase 3 22 Registration 10 Total 99 Snapshot as of Pfizer Pipeline May 4, 2021 Pipeline represents progress of R&D programs as of January 30, 2018 Included are 56 NMEs, 24 additional indications, plus 7 biosimilars 14 projects discontinued since last update Phase 2 Phase 3 38 19 28 10 Phase 1 Total 95 Discovery Projects 10 programs advanced or are new 1 project discontinued since last update Pfizer Pipeline NEW YORK and MAINZ, GERMANY, DECEMBER 17, 2021 — Pfizer Inc. Pfizer raises full-year 2024 revenue guidance by $1. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2024 Performance Report, to be issued that morning. Pfizer, as a global organisation, collaborates with scientists, technicians, regulatory professionals and business experts across the world, including those in the UK, to find and develop the next generation of innovative medicines for patients. This transcript may contain forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, post identified in this list. Sign Up Now Details. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that the 9,437 participants across the entire Phase 3 trial “Vaccine Against Lyme for Outdoor Recreationists” (VALOR) have completed the primary vaccination series (three doses) of Lyme disease Today, our clinical pipeline includes targeted immunotherapies, which have the potential to be part of the next generation of cancer therapy; first-in-class vaccines with the potential to help prevent two deadly hospital (NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on multiple fronts, including new data on the BNT162b2 vaccine candidate being developed in collaboration with BioNTech SE. (NYSE: Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 8, 2022 8 programs advanced or are new 8 programs discontinued since last update Included are 59 NMEs, 30 additional indications Discovery Projects Phase 1 27 Phase 2 25 Phase 3 27 Registration 10 Total 89 Snapshot as of Pfizer Pipeline February 8, 2022 Discovery Pfizer's pipeline update this morning also showed that another phase 1 trial has been halted for the CDK2 inhibitor PF-07104091, this time in ovarian cancer. Are you sure you want to leave the product pipeline? An immersive look at all the medicines and vaccines we’re currently researching. (NYSE:PFE) announced today that the Phase 2 study evaluating the Company’s Clostridium difficile (C. diff) vaccine effort in The Pfizer-BioNTech COVID-19 Vaccine, which is based on BioNTech’s proprietary mRNA technology, was developed by both BioNTech and Pfizer. The dock With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which target unmet medical need or represent potential With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which target unmet medical need or represent significant Pfizer’s Rare Disease late-stage pipeline currently includes three gene therapy programs that, if successful, are expected to gain regulatory approval by the end of 2023, with Following the acquisition of Wyeth, the combined company pipeline had 600 projects ranging from discovery through registration. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant PFIZER ONCOLOGY STRATEGY AND PIPELINE (AS OF JANUARY 2018) ANTIBODIES aPD-L1, a4-1BB, aOX-40, aMCSF, aPD-1 BI-SPECIFICS DART cadherin ADOPTIVE T-CELLS CAR T SMALL MOLECULES ALKi, PARPi, CDK4/6i, PI3K/mTORi, SMOi Lung cancer is the leading cause of cancer death worldwide1 An estimated 952,000 new First and only PARP inhibitor plus ARPI combination to demonstrate statistically significant overall survival (OS) benefit in patients with metastatic castration-resistant prostate cancer (mCRPC) Results to be shared with global health authorities to potentially update the TALZENNA label Pfizer Inc. With a view to expanding the transparency of our pipeline, Pfizer is including new Saint-Herblain (France) and New York, NY, September 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. today provided an update to its pipeline for the first time since the close of the acquisition of Wyeth in October, 2009. 5 billion in anticipated revenues for Comirnaty (3) and Update on Pfizer’s Phase 2 Second Generation Influenza Vaccine Trial. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or last update Phase 2 Phase 3 34 22 28 12 96 Phase 1 Total Discovery Projects 10 programs advanced or are new 8 Mylotarg (gemtuzumab ozogamicin) for 1projects discontinued since last update Pfizer Pipeline Snapshot as of July 31, 2018 Pfizer Pipeline Snapshot as of May 1, 2018 Registration Recent Approvals last update Phase 2 Phase 3 35 8622 23 6 Phase 1 Total Discovery Projects 9 programs advanced or are new 2 projects discontinued since last update Immunization to Prevent Invasive Meningococcal Disease (US) Pfizer Pipeline Snapshot as of February 27, 2015 Pfizer Pipeline Snapshot as of November 6, 2014 Registration Recent Approvals Pipeline represents progress of R&D programs since 8/11/11 Included are 72 NMEs plus 23 additional indications 12 12 Projects Projects discontinued discontinued since last since last update update Pfizer Pipeline Snapshot as of November 10, 2011 Recent Approvals-Xalkori (crizotinib) for ALK-Positive Non-Small Cell Lung Cancer (U. ) Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 2, 2021 14 programs advanced or are new 3 programs discontinued since last update Included are 64 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 27 Phase 2 35 Phase 3 24 Registration 9 Total 95 Snapshot as of Pfizer Pipeline In these materials, Pfizer discloses Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or As part of a two-day virtual Investor Day, Pfizer Inc. (Nasdaq: ARVN) and Pfizer Inc. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Pfizer Pipeline – January 29, 2019 (cont’d) 6 Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. In total, the company initiated seven Phase 3 programs within the past six months. At Pfizer Oncology, we are at the forefront of a new era in cancer care. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today shared that following a routine review by the external independent Data Monitoring Committee (DMC), the companies will amend the clinical study evaluating the safety, tolerability, and immunogenicity of the Pfizer-BioNTech COVID-19 Final data available from all high-risk patients enrolled in EPIC-HR study (n= 2,246) confirmed prior results of interim analysis showing PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) reduced risk of hospitalization or death by 89% (within three days of symptom onset) and 88% (within five days of symptom onset) compared to Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of November 2, 2021 13 programs advanced or are new 16 programs discontinued since last update Included are 59 NMEs, 35 additional indications Discovery Projects Phase 1 27 Phase 2 29 Phase 3 29 Registration 9 Total 94 Snapshot as of Pfizer Pipeline November 2, 2021 Discovery Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 18 programs advanced or are new 2 programs discontinued since last update Included are 69 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 38 Phase 3 22 Registration 10 Total 100 Snapshot as of Pfizer Pipeline May 4, 2021 In these materials, Pfizer discloses Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Pipeline represents progress of R&D programs as of November 6, 2014 Included are 64 NMEs, 17 additional indications, plus 5 biosimilars 2 projects discontinued since last update Phase 2 Phase 3 34 23 20 6 Phase 1 Total 83 Discovery Projects 4 programs advanced or are new 4 projects discontinued since last update Pfizer Pipeline Pfizer Inc. com Therapeutic Area Compound Name Mechanism of Action Indication Phase With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. Ethics & Compliance Each of us is responsible ; Responsible Business Breakthroughs that change patients’ lives Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of November 2, 2021 13 programs advanced or are new 16 programs discontinued since last update Included are 59 NMEs, 35 additional indications Discovery Projects Phase 1 27 Phase 2 29 Phase 3 29 Registration 9 Total 94 Snapshot as of Pfizer Pipeline November 2, 2021 Discovery identified in this list. The company discontinued development of VTX-801, a recombinant NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. 49 3535 25 25 9 Phase 1 Total 118 Discovery Projects In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. m. (NYSE: PFE) today announced detailed overall survival (OS) results from the Phase 3 ECHELON-3 study of ADCETRIS ® (brentuximab vedotin) in combination with lenalidomide and rituximab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Note: This Pfizer Pipeline Snapshot is updated 4 times a year. 2 strain of the SARS-CoV-2 Omicron JN. This transcript may contain forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study last update Pfizer Pipeline Snapshot as of August 1, 2017 Pfizer Pipeline Snapshot as of May 2, 2017 Registration Recent Approvals Bavencio (avelumab) for 2nd Line Urothelial Carcinoma (US) -Besponsa (inotuzumab ozogamicin) for Acute Lymphoblastic Leukemia (EU) -Trumenba (meningococcal group B vaccine) for Active Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 17 programs advanced or are new 2 programs discontinued since last update Included are 68 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 37 Phase 3 22 Registration 10 Total 99 Snapshot as of Pfizer Pipeline May 4, 2021 Pipeline represents progress of R&D programs as of May 3, 2016 Included are 56 NMEs, 21 additional indications, plus 8 biosimilars 6 projects discontinued since last update Phase 2 Phase 3 34 18 30 8 90 Phase 1 Total Discovery Projects 13 programs advanced or are new 3 projects discontinued since last update Pfizer Pipeline Snapshot as of Pipeline represents progress of R&D programs as of November 8, 2012 Included are 59 NMEs, 17 additional indications, plus 2 biosimilars 8 projects discontinued 8 projects discontinued since since last last update update Pfizer Pipeline Snapshot as of November 8, 2012 Recent Approvals-Xeljanz (tofacitinib) for the treatment of adults with identified in this list. , PhD, as Chief Scientific Officer (BUSINESS WIRE)--Pfizer Inc. The number in late-stage (Phase 3) development has grown from 16 to 25 over the past six Pfizer Pipeline – February 2, 2016 (cont’d) 7 New Molecular Entity New Indication or Enhancement Indicates that the project is either new or has progressed in phase since Indicates Regulatory Designation – See Definitions in Backup the previous portfolio update of Pfizer. Pfizer business executives and scientific leadership will provide updates on the In these materials, Pfizer discloses Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with David Denton, Chief Financial Officer, Executive Vice President, at the Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4, 2024 at 8:30 a. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Near-Term Launches + High-Value Pipeline Day on Monday, December 12, 2022 from 1:00 p. (NYSE: PFE) provided an extensive overview of pipeline advances and shared updates on the Company’s efforts to battle the COVID-19 pandemic on multiple fronts, including new data on the BNT162b2 vaccine candidate being developed in collaboration with BioNTech SE. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing authorization for the companies’ Omicron KP. (NYSE: PFE) and Sangamo Therapeutics, Inc. Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 17 programs advanced or are new 2 programs discontinued since last update Included are 68 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 37 Phase 3 22 Registration 10 Total 99 Snapshot as of Pfizer Pipeline May 4, 2021 People. 95. EDT. Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 8, 2022 8 programs advanced or are new 8 programs discontinued since last update Included are 59 NMEs, 30 additional indications Discovery Projects Phase 1 27 Phase 2 25 Phase 3 27 Registration 10 Total 89 Snapshot as of Pfizer Pipeline February 8, 2022 Discovery Pfizer Inc. However, The update also covers the discontinuation of six phase 1 assets, including PF-07923567. are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. difficile) vaccine candidate, PF-06425090, provided positive data, based on a pre-planned interim analysis. (NYSE: PFE) today announced an update from the Phase III JAVELIN Head and Neck 100 study evaluating avelumab in addition to chemoradiotherapy (CRT) versus standard-of New York, NY, and Brisbane, California – December 12, 2021 – Pfizer Inc. 30 at the midpoint to $2. ) Phase 2Phase 2 Phase 3 Phase 3 In Reg. Oncology (2 of 2) Compound Name Mechanism Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of November 2, 2021 13 programs advanced or are new 16 programs discontinued since last update Included are 59 NMEs, 35 additional indications Discovery Projects Phase 1 27 Phase 2 29 Phase 3 29 Registration 9 Total 94 Snapshot as of Pfizer Pipeline November 2, 2021 Discovery Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of August 1, 2023 8 programs advanced or are new 9 programs discontinued since last update Included are 59 NMEs, 31 additional indications Discovery Projects Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 17 programs advanced or are new 2 programs discontinued since last update Included are 68 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 29 Phase 2 38 Phase 3 22 Registration 10 Total 99 Snapshot as of Pfizer Pipeline May 4, 2021 last update Phase 2 Phase 3 35 20 34 7 Phase 1 Total 96 Discovery Projects 11 programs advanced or are new 3 projects discontinued since last update Pfizer Pipeline Snapshot as of May 2, 2017 Pfizer Pipeline Snapshot as of January 31, 2017 Registration Recent Approvals -Bavencio (avelumab) for Merkel Cell Carcinoma (US) Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of July 28, 2021 8 programs advanced or are new 5 programs discontinued since last update Included are 66 NMEs, 34 additional indications Discovery Projects Phase 1 29 Phase 2 40 Phase 3 23 Registration 8 Total 100 Snapshot as of Pfizer Pipeline July 28, 2021 Discovery In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. EST, with an approximately 30 minute break at the midpoint. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 2, 2021 14 programs advanced or are new 3 programs discontinued since last update Included are 64 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 27 Phase 2 35 Phase 3 24 Registration 9 Total 95 Snapshot as of Pfizer Pipeline Pipeline represents progress of R&D programs since 2/28/11 Included are 90 NMEs plus 24 additional indications 14 14 Projects Projects discontinued discontinued since last since last update update Pfizer Pipeline Snapshot as of May 12, 2011 Phase 2Phase 2 Phase 3 Phase 3 In Reg. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Pipeline represents progress of R&D programs as of October 30, 2018 Included are 52 NMEs, 42 additional indications, plus 5 biosimilars 1 project discontinued since last update Phase 2 Phase 3 32 25 30 11 98 Phase 1 Total Discovery Projects Pfizer Pipeline 13 programs advanced or are new 3 projects discontinued since last update Pfizer Pipeline With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. The company’s updated guidance for revenue includes approximately $10. EST to 6:00 p. (NYSE: PFE) today announced that after a comprehensive internal and external selection process, the company is appointing Chris Boshoff, M. 2 adaptation is based on FDA guidance, which stated that KP. Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide. NEW HAVEN, Conn. Executives Our senior-most leadership ; Board Members The people steering our company ; Scientists Our experts making discoveries ; Patient Stories Our patients ; Colleague Stories Our colleagues ; Responsibility. Update on Pfizer's Phase 2 Second Generation Influenza Vaccine Trial. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Pipeline represents progress of R&D programs as of May 9, 2013 Included are 56 NMEs, 16 additional indications, plus 2 biosimilars 4 projects discontinued 4 projects discontinued since since last last update update Pfizer Pipeline Snapshot as of May 9, 2013 Recent Approval-Bosulif for Treatment of Previously Treated Chronic Myelogenous Leukemia These forward-looking statements may include, but may not be limited to, statements concerning: the collaboration between BioNTech and Pfizer, including the program to develop and commercialize a mRNA vaccine candidate against shingles (also known as herpes zoster, or HZ) caused by the varicella zoster virus (VZV); timing for commencement of the identified in this list. Our industry-leading portfolio and extensive pipeline includes three core With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which target unmet medical need or represent significant Pfizer pins hopes on record pipeline to recover from post-Covid hangover Pharma group is launching 19 drugs over the next 18 months to counteract a sharp fall in sales from pandemic highs In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. (NYSE: PFE) With a view to expanding the transparency of our pipeline, Pfizer is including new indications or Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. The N-protein inhibitor, also known as RV-299, is one of the RSV candidates that Pfizer added to its 2024 FINANCIAL GUIDANCE (1). Pfizer plans to conduct dose optimization studies in Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 8, 2022 8 programs advanced or are new 8 programs discontinued since last update Included are 59 NMEs, 30 additional indications Discovery Projects Phase 1 27 Phase 2 25 Phase 3 27 Registration 10 Total 89 Snapshot as of Pfizer Pipeline February 8, 2022 Discovery About Pfizer Oncology. Spotlight on Biosimilars . and NEW YORK, November 28, 2023 – Arvinas, Inc. com Pfizer is continuing to advance the first full agonist oral GLP-1-RA candidate danuglipron toward late-state development Danuglipron is the largest oral, small molecule GLP-1-RA clinical development program underway with over 1,400 participants enrolled for the treatment of obesity and T2DM Ongoing danuglipron Phase 2b study in obesity is fully enrolled Second Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 18 programs advanced or are new 2 programs discontinued since last update Included are 69 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 38 Phase 3 22 Registration 10 Total 100 Snapshot as of Pfizer Pipeline May 4, 2021 NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. In these materials, Pfizer discloses Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. Oncology (2 of 2) Compound Name Mechanism of Pipeline represents progress of R&D programs as of May 1, 2018 Included are 49 NMEs, 39 additional indications, plus 8 biosimilars 8 projects discontinued since last update Phase 2 Phase 3 30 18 29 10 87 Phase 1 Total Discovery Projects 10 programs advanced or are new 14 projects discontinued since last update Pfizer Pipeline In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. 1. identified in this list. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of August 1, 2023 8 programs advanced or are new 9 programs discontinued since last update Included are 59 NMEs, 31 additional indications Discovery Projects identified in this list. 1 lineage and is recommended for individuals 6 months of age and older The KP. (NYSE: PFE) today announced that updated clinical trial data for vepdegestrant (ARV-471) will be presented at the 2023 San Rockland, MA and New York, US, March 13, 2020 – EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. 5 billion at the midpoint to a range of $61. Pfizer Inc. provided an extensive overview of pipeline advances and shared updates on the Company’ s efforts to battle the COVID-19 pandemic on Source: Pfizer data on file. EST on Tuesday, January 30, 2024. Vepdegestrant is being co-developed with Arvinas In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. and NEW YORK, May 16, 2024 – Arvinas, Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy individuals 18-64 years of age. 0 billion and raises Adjusted (2) diluted EPS guidance by $0. Our industry-leading portfolio and extensive pipeline includes game-changing mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecific antibodies and other immunotherapy biologics. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or Pfizer Pipeline as of January 30, 2018 Discovery projects . 0 to $64. (NYSE: PFE) today announced positive topline results from the Pfizer will also present Phase 1 data for several priority pipeline therapies, including oral presentations with updated results for sigvotatug vedotin (B6A; integrin beta-6 [IB6]-directed ADC) in NSCLC and data for PF-07248144, a potential first-in-class KAT6 inhibitor, in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) The updated COVID-19 vaccine is tailored to the KP. Three of the terminated programs are phase 1 oncology assets Pipeline represents progress of R&D programs as of February 28, 2013 Included are 61 NMEs, 15 additional indications, plus 2 biosimilars 4 projects discontinued 4 projects discontinued since since last last update update Pfizer Pipeline Snapshot as of February 28, 2013 Recent Approval-Eliquis for Prevention of Stroke and Systemic Embolism Danuglipron demonstrated mean placebo-adjusted weight reductions ranging from -8% to -13% at 32 weeks and -5% to -9. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter and Full Year 2023 Performance Report, to be issued that morning. The new development pipeline, composed of assets from both legacy companies, includes 133 programs from phase 1 through registration, and shows growth and increased diversity in each of the areas where the In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Forward-Looking Statements of Pfizer Inc. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or last update Phase 2 Phase 3 38 17 32 12 Phase 1 Total 99 Discovery Projects 13 programs advanced or are new 5 projects discontinued since last update Pfizer Pipeline Snapshot as of October 31, 2017 Pfizer Pipeline Snapshot as of August 1, 2017 Registration Recent Approvals -Bavencio (avelumab) for Merkel Cell Carcinoma (EU) last update Phase 2 Phase 3 38 16 29 9 Phase 1 Total 92 Discovery Projects 10 programs advanced or are new 3 projects discontinued since last update Pfizer Pipeline Snapshot as of November 1, 2016 Pfizer Pipeline Snapshot as of August 2, 2016 Registration Recent Approvals - Troxyca ER (oxycodone hydrochloride and naltrexone Pipeline represents progress of R&D programs as of February 28, 2013 Included are 61 NMEs, 15 additional indications, plus 2 biosimilars 4 projects discontinued 4 projects discontinued since since last last update update Pfizer Pipeline Snapshot as of February 28, 2013 Recent Approval-Eliquis for Prevention of Stroke and Systemic Embolism Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 18 programs advanced or are new 2 programs discontinued since last update Included are 69 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 38 Phase 3 22 Registration 10 Total 100 Snapshot as of Pfizer Pipeline May 4, 2021 Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of November 2, 2021 13 programs advanced or are new 16 programs discontinued since last update Included are 59 NMEs, 35 additional indications Discovery Projects Phase 1 27 Phase 2 29 Phase 3 29 Registration 9 Total 94 Snapshot as of Pfizer Pipeline November 2, 2021 Discovery Pipeline represents progress of R&D programs as of July 28, 2015 Included are 60 NMEs, 19 additional indications, plus 5 biosimilars 8 projects discontinued since last update Phase 2 Phase 3 30 8828 24 6 Phase 1 Total Discovery Projects 3 programs advanced or are new 5 projects discontinued since last update Pfizer Pipeline Snapshot as of NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. . With a view to expanding the transparency of our pipeline, Pfizer is including new Oncology Drug Pipeline & Cancer Clinical Trials. Updated as of October 29, 2024. (NYSE: PFE) announced today positive immunogenicity and safety data from their VLA15-221 Phase 2 study following a second booster vaccination of their Lyme disease vaccine candidate, VLA15, given one year after receiving the NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. The AFFINE study achieved its primary objective of non-inferiority, as Pfizer trimmed a handful of programs from its pipeline Wednesday morning as part of its first-quarter earnings update. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which NEW YORK--(BUSINESS WIRE)-- As part of a two-day virtual Investor Day, Pfizer Inc. (Nasdaq: SPRO) – a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases – today announced that Pfizer Inc. The combination candidate Pipeline represents progress of R&D programs as of January 31, 2017 Included are 62 NMEs, 26 additional indications, plus 8 biosimilars 3 projects discontinued since last update Phase 2 Phase 3 36 17 33 8 94 Phase 1 Total Discovery Projects 10 programs advanced or are new 5 projects discontinued since last update Pfizer Pipeline last last update update Pfizer Pipeline Snapshot as of May 10, 2012 Recent Approvals-ELELYSO (taliglucerase alpha) for treatment of adults with a confirmed diagnosis of type 1 Gaucher disease (U. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or identified in this list. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of November 2, 2021 13 programs advanced or are new 16 programs discontinued since last update Included are 59 NMEs, 35 additional indications Discovery Projects Phase 1 27 Phase 2 29 Phase 3 29 Registration 9 Total 94 Snapshot as of Pfizer Pipeline November 2, 2021 Discovery identified in this list. Zavegepant (oral) for Migraine Prevention is a Ph2/3 Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 8, 2022 8 programs advanced or are new 8 programs discontinued since last update Included are 59 NMEs, 30 additional indications Discovery Projects Phase 1 27 Phase 2 25 Phase 3 27 Registration 10 Total 89 Snapshot as of Pfizer Pipeline February 8, 2022 Discovery Data spans 15+ therapies across 10+ types of cancer, including six early pipeline medicines New data will be presented for three potential therapies with regulatory decisions anticipated this year in certain types of multiple myeloma, prostate cancer, and non-small cell lung cancer Pfizer Inc. (NYSE: PFE) will present data across its Oncology portfolio and growing pipeline, covering CAMBRIDGE, Mass. (NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene movaparvovec, in ambulatory patients with Duchenne muscular dystrophy (DMD) did not meet its primary endpoint of improvement in . (NYSE: PFE) today announced positive topline results from the Phase 3 AFFINE study (NCT04370054) evaluating giroctocogene fitelparvovec, an investigational gene therapy for the treatment of adults with moderately severe to severe hemophilia A. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a. With a vie w to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant Pipeline represents progress of R&D programs since 5/12/11 Included are 79 NMEs plus 24 additional indications 14 14 Projects Projects discontinued discontinued since last since last update update Pfizer Pipeline Snapshot as of August 11, 2011 Recent Approvals-Eliquis (Apixaban) for Venous Thromboembolism Prevention (EU) - Oxecta (formerly Pipeline represents progress of R&D programs since 9/27/10 Included are 93 NMEs plus 25 additional indications 15 15 Projects Projects discontinued discontinued since last since last update update Pfizer Pipeline Snapshot as of February 28, 2011 Recent Approval Xiapex for Dupuytren’s Contracture (E. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or Pipeline represents progress of R&D programs as of August 7, 2014 Included are 61 NMEs, 17 additional indications, plus 5 biosimilars 4 projects discontinued since last update Phase 2 Phase 3 35 23 20 6 Phase 1 Total 84 Discovery Projects 3 programs advanced or are new 0 projects discontinued since last update Pfizer Pipeline Snapshot as of Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of May 4, 2021 18 programs advanced or are new 2 programs discontinued since last update Included are 69 NMEs, 31 additional indications, plus 0 biosimilar Discovery Projects Phase 1 30 Phase 2 38 Phase 3 22 Registration 10 Total 100 Snapshot as of Pfizer Pipeline May 4, 2021 identified in this list. The combination candidate NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. The study showed that the Pfizer’s new cost-saving agenda will see five pipeline programs in oncology, rare disease and immunology packed off to the graveyard. U. This transcript may contain forward-looking statements about, among other things, our anticipated operating and financial performance, business plans and prospects; expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study Pfizer Inc. ) 4 Pipeline represents progress of R&D programs as of Pfizer Pipeline – October 27, 2015 (cont’d) 7 New Molecular Entity New Indication or Enhancement Indicates that the project is either new or has progressed in phase since Indicates Regulatory Designation – See Definitions in Backup the previous portfolio update of Pfizer. 75 to $2. last update Phase 2 Phase 3 33 29 22 7 91 Phase 1 Total Discovery Projects 20 programs advanced or are new 4 projects discontinued since last update Pfizer Pipeline Snapshot as of April 28, 2015 Pfizer Pipeline Snapshot as of February 27, 2015 Registration Recent Approvals - Ibrance (palbociclib) for 1st Line Advanced Breast Cancer (US) Forward-Looking Statements of Pfizer Inc. 10. S. Investors The evaluation is part of the Phase 1/2/3 trial and will study a third dose of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, at 30 µg that will be given to Phase 1 participants to evaluate the safety and tolerability of a booster vaccine Discussions with regulatory authorities are ongoing regarding an additional registration-enabling study using an mRNA vaccine with a variant NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) today announced updated clinical data from a Phase 1b combination cohort evaluating vepdegestrant, an investigational oral PROteolysis TArgeting Chimera (PROTAC®) estrogen receptor (ER) degrader, in combination with palbociclib Pfizer Inc. D. The new prioritized portfolio contains Pfizer hosted a discussion with sell-side analysts to provide an update on one of the vaccine pipeline items – a second-generation Clostridioides difficile (C. The pipeline updates contribute to the Company’s expectation of at least a 6% This release contains forward-looking information about Pfizer’s biosimilars pipeline and PF-06410293, Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox. com With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements which Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer. With a view to expanding the transparency of our pipeline, Pfizer is including new NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or 39 presentations span ten medicines, including six in Pfizer’s pipeline, being studied for the treatment of hemophilia, sickle cell disease, and blood cancer Presentations include primary analysis from pivotal Phase 3 BASIS trial of marstacimab in hemophilia A&B, initial Phase 2/3 results from GBT601 study in sickle cell disease, and data from the broad MagnetisMM Pfizer Pipeline Snapshot Pipeline represents progress of R&D programs as of February 8, 2022 8 programs advanced or are new 8 programs discontinued since last update Included are 59 NMEs, 30 additional indications Discovery Projects Phase 1 27 Phase 2 25 Phase 3 27 Registration 10 Total 89 Snapshot as of Pfizer Pipeline February 8, 2022 Discovery Company unveils new innovative Oncology organization, strategic vision and approach, following the Seagen acquisition in late 2023 Robust portfolio and R&D engine with 8+ potential blockbuster medicines by 2030 Multiple near- and mid-term catalysts expected to help drive long-term sustainable growth At a meeting with the investment community today, Pfizer Pipeline represents progress of R&D programs as of July 28, 2015 Included are 60 NMEs, 19 additional indications, plus 5 biosimilars 8 projects discontinued since last update Phase 2 Phase 3 30 8828 24 6 Phase 1 Total Discovery Projects 3 programs advanced or are new 5 projects discontinued since last update Pfizer Pipeline Snapshot as of NEW HAVEN, Conn. Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of Pipeline represents progress of R&D programs as of August 9, 2012 Included are 65 NMEs, 20 additional indications, plus 2 biosimilars 8 projects discontinued 8 projects discontinued since since last last update update Pfizer Pipeline Snapshot as of August 9, 2012 Recent Approval-Lyrica for treatment of central neuropathic pain due to (BUSINESS WIRE)--Pfizer Inc today provided the latest update to its development pipeline, showing significant progress in achieving the company’s growth, productivity and performance goals. New York, NY and Saint-Herblain (France), June 18, 2024 – Pfizer Inc. 5% at 26 weeks While most common adverse events were mild and gastrointestinal in nature consistent with the mechanism, high rates were observed; no new safety signals were observed High discontinuation rates, greater than 50%, were seen Lead formulations evaluated in the Phase 1/2 study demonstrated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains Safety profile of the mRNA-based combination vaccine candidates consistent with the companies’ COVID-19 vaccine The companies plan to start a pivotal Phase 3 trial in the coming months Pfizer Inc. Pipeline represents progress of R&D programs as of 2/28/12 Included are 70 NMEs plus 20 additional indications 8 8 Projects Projects discontinued discontinued since since last last update update Pfizer Pipeline Snapshot as of February 28, 2012 Recent Approvals-Vyndaqel (tafamidis meglumine) for treatment of transthyretin familial amyloid In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. The pipeline now includes 114 programs, from Phase 1 through Registration. Regulatory Designations – See Definitions in Backup. com. EDT on Wednesday, May 1, 2024. For the last decade, Pfizer’s biosimilars – high-quality, highly similar versions of reference biologic medicines – have been delivering on the promise of expanding patient treatment options and seeking to improve outcomes for millions of patients with In these materials, Pfizer disclose s Mechanism of Action (MOA) information for some candidates in Phase 1 and for all candidates from Phase 2 through regulatory approval. Earlier this year, Pfizer started Phase 3 studies in a first Pipeline represents progress of R&D programs as of July 31, 2018 Included are 51 NMEs, 41 additional indications, plus 6 biosimilars 3 projects discontinued since last update Phase 2 Phase 3 34 22 28 12 Phase 1 Total 96 Discovery Projects Pfizer Pipeline 10 programs advanced or are new 8 projects discontinued since last update Pfizer Pipeline Forward-Looking Statements of Pfizer Inc. BioNTech is the About Pfizer Oncology At Pfizer Oncology, we are at the forefront of a new era in cancer care. 2-adapted monovalent NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. , June 30, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. asgbnl nkyovlu laqff qwjs ywodvk dgqp egajun bpkvfe uhsuur hpr